Amenamevir

Amenamevir

Amenamevir

Chemical compound

Amenamevir (trade name Amenalief) is an antiviral drug used for the treatment of shingles (herpes zoster).

Quick Facts Clinical data, Trade names ...

It acts as an inhibitor of the zoster virus's helicase–primase complex.[1][2] Amenamevir was approved in Japan for the treatment of shingles in 2017.[3]

See also

References

  1. [1]
    Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, et al. (November 2017). "Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study". The Journal of Dermatology. 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394.
  2. [2]
    Yajima M, Yamada H, Takemoto M, Daikoku T, Yoshida Y, Long T, et al. (March 2017). "Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor". Antiviral Research. 139: 95–101. doi:10.1016/j.antiviral.2016.12.008. PMID 28027917. S2CID 43813287.
  3. [3]
    "Maruho Receives Manufacturing and Marketing Approval for Anti-Herpes Virus Agent "Amenalief® Tab. 200mg" in Japan" (Press release). evaluategroup.com. July 3, 2017.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Amenamevir, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.